Latest Macular edema Stories
Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes. The study, which was partly funded by the Juvenile Diabetes Research Foundation (JDRF), is published in the...
ATLANTA, Dec. 11 /PRNewswire/ -- Alimera Sciences Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(TM) in patients with bilateral geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The pilot study will compare two doses of Iluvien (0.23 and...
ATLANTA, Oct. 1 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim month six safety and efficacy results from the first human pharmacokinetic (PK) study of Iluvien(TM). Iluvien is an intravitreal insert being developed for the treatment of diabetic macular edema (DME). DME is a disease of the retina, which affects...
Novagali Pharma, an ophthalmic pharmaceutical company, has secured E15 million in a new financing round with the participation of the historical company investors. The company said that it will use the proceeds to continue development of its high potential projects: the commercialization in France and abroad of its first marketable product, Cationorm, indicated for the treatment of dry eye symptoms; and the development of its flagship products - Vekacia (vernal keratoconjunctivitis),...
ATLANTA, Sept. 24 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has again recommended that the two pivotal Phase 3 clinical trials for the use of Iluvien(TM) in the treatment of diabetic macular...
BOSTON "” July 14, 2005 "” A multicenter international study chaired by a Joslin Diabetes Center investigator and reported in the July issue of the American Diabetes Association's journal Diabetes brings hopeful news to the 18 million people in the United States "” and millions more worldwide "” with type 1 or type 2 diabetes. Initial results of the Phase III clinical trial demonstrated that 32 milligrams per day of ruboxistaurin (RBX) was well tolerated and may reduce the risk of...
